This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
by Sweta Killa
Sector ETF report for PBE
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
Trump's Approval Rises Before Midterms: ETFs to Lose/Gain
by Sanghamitra Saha
Recent improvement in Trump's approval rating puts these ETFs in focus.
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
4 Sector ETFs That Crushed S&P 500 in Longest Bull Market
by Sanghamitra Saha
These sector ETFs outperformed the S&P 500 in the longest-ever bull market.
What Investors Need to Know about Biotech ETFs
by Neena Mishra
Smaller biotech stocks are outperforming this year; learn more about biotech ETFs best positioned to benefit
Sarepta Pharma Pushes Two Biotech ETFs to New Highs
by Sweta Killa
The encouraging early trial results for a gene therapy for Duchenne muscular dystrophy pushed Sarepta Therapeutics and few biotech ETFs to new highs.
Should You Invest in the PowerShares Dynamic Biotechnology & Genome Portfolio (PBE)?
by Sweta Killa
Sector ETF report for PBE
Is PowerShares Dynamic Biotechnology & Genome Portfolio (PBE) a Hot ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PBE
Biotech ETFs Head to Head: XBI vs. IBB.
by Zacks Equity Research
Head-to-head comparison of two Biotech ETFs, XBI and IBB.
Biotech ETF (XBI) Hits New 52-Week High
by Sanghamitra Saha
This biotech ETF hit a new 52-week high. Are more gains in store for this fund?
Rush for Marijuana ETFs Getting Stronger
by Sanghamitra Saha
Teucrium plans for an Emerging Medical Agriculture Index Fund. Does this hint at a marijuana ETF?
Biotech ETFs: What Lies Ahead?
by Zacks Equity Research
It's been a good year for biotech ETFs, can the rally continue?
Can Biotech ETFs Continue to Surge Higher?
by Zacks Equity Research
There are several reasons to be positive on biotech stocks and ETFs for the rest of the year.
The Zacks Analyst Blog Highlights: SPDR Technology ETF, SPDR S&P Biotech ETF, First Trust NYSE Arca Biotechnology Index Fund, BioShares Biotechnology Products ETF and SPDR Healthcare ETF
by Zacks Equity Research
The Zacks Analyst Blog Highlights: SPDR Technology ETF, SPDR S&P Biotech ETF, First Trust NYSE Arca Biotechnology Index Fund, BioShares Biotechnology Products ETF and SPDR Healthcare ETF
How Kite Pharma Is Revolutionizing the Fight Against Cancer
by Eric Dutram
Immunotherapy is a hot corner of the biotech world. Learn how companies in this sector fight cancer in this podcast which features Dr. David Chang, the Chief Medical Officer of Kite Pharma. Do not miss it!
Republicans Present Healthcare Bill: Top 5 Gainers
by Tirthankar Chakraborty
Healthcare stocks posted record highs, with hospitals and insurers climbing after Senate Republicans released a draft bill to replace Obamacare.
The Latest Market Trends Every Biopharma Investor Needs to Know
by Ryan McQueeney
Speaking at MedCity INVEST, a national healthcare investing conference in Chicago hosted by MedCity News, Jonathan Norris of Silicon Valley Bank, alongside Ryan Jalowiecki from PwC, highlighted the latest trends in the public healthcare markets. If you are a serious biopharma investor, you won't want to miss this.
Time to Buy Biotech ETFs?
by Zacks Equity Research
After a painful 2016, biotech stocks are recovering this year. What lies ahead?
Trump's Immigration Plans an Overhang on Biotech ETFs?
by Zacks Equity Research
Immigration related uncertainty has put biotech ETFs in focus.
ETF Industry to Get a Product on Marijuana?
by Sanghamitra Saha
A new fund has been filed targeting the medical marijuana industry.
What Lies Ahead for Biotech ETFs in Trump Era?
by Zacks Equity Research
Despite political risks, there are many factors supporting growth in the biotech sector.
Trump Vows to Slash Drug Prices, Sends Biotech Stocks Lower
by Ryan McQueeney
Shares of the iShares Nasdaq Biotechnology ETF (IBB) are down more than 3.6% in morning trading Wednesday following a new warning from President-elect Donald Trump that he will indeed be targeting high drug prices.
What Investors Need to Know About Biotech ETF Investing
by Eric Dutram
Taking a look at 3 key factors to evaluate when you are considering a biotech ETF.
How to Invest in Leveraged Biotechnology ETFs
by Eric Dutram
What investors need to know about leveraged and inverse biotechnology ETF investing.